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ABSTRACT

Provided are bis-quaternary ammonium cyclophane com
pounds Which are modulators of nicotinic acetylcholine
receptors. Also provided are methods of using the compounds
for modulating the function of a nicotinic acetylcholine
receptor, and for the prevention and/ or treatment of central
nervous system disorders, substance use and/or abuse, and or

gastrointestinal tract disorders.
(2006.01)
(2006.01)

9 Claims, No Drawings

US 8,653,275 B2
1

2

BIS-QUATERNARY AMMONIUM

methyllycaconitine (MLA), Which has high af?nity for the (X7
nicotinic receptor subtype. Nicotinic receptor subtypes can

CYCLOPHANE COMPOUNDS THAT
INTERACT WITH NEURONAL NICOTINIC
ACETYLCHOLINE RECEPTORS

be studied using functional assays, such as NIC-evoked neu

rotransmitter release (e.g., [3H]dopamine (DA) release, [3 H]
norepinephrine (NE) release, [3H]serotonin (5-HT) release,
[3H]gamma-aminobutyric acid (GABA) release and [3 H]

CONTINUING APPLICATION DATA

glutamate release) from superfused rat brain slices. Nicotinic
This application is a national stage of PCT/US2007/

receptors are located in the cell body and terminal areas of
these neurotransmitter systems. NIC facilitates neurotrans
mitter release from nerve terminals.
The structural and functional diversity of central nervous
system nicotinic receptors has stimulated a great deal of inter

011269, ?led May 11, 2007, Which claims bene?t of US.

Provisional Application No. 60/799,881, ?led May 12, 2006,
Which is incorporated herein by reference in its entirety.
IDENTIFICATION OF FEDERAL FUNDING

est in developing novel, subtype-selective agonists and/or
antagonists. Some of these agonists are currently being evalu

The present invention Was supported by Grant NIH
U19DA017548 from the National Institutes of Health, and
therefore the government may have rights in the invention.

protective effects, potentially bene?cial for disease states

FIELD OF THE INVENTION

treatment of drug abuse, depression, obesity and pain relief.

ated in clinical trials for cognitive enhancement and neuro
such as AlZheimer’s and Parkinson’s disease, as Well as for
20

SUMMARY OF THE INVENTION

The invention relates to bis-quatemary ammonium cyclo
phane compounds that interact With neuronal nicotinic recep
tors, and to methods of using the compounds to treat central
nervous system diseases and pathologies.

In one embodiment, compounds corresponding to the fol
loWing structure are provided.
25

BACKGROUND OF THE INVENTION

Q

S(—)-Nicotine (NIC) activates presynaptic and postsynap

(I)

tic neuronal nicotinic receptors that evoke the release of neu

rotransmitters from presynaptic terminals and that modulate
the depolariZation state of the postsynaptic neuronal mem

30

brane, respectively. Thus, nicotine produces its effect by

X16 and X26 are each independently an organic or inor

ganic anion.

binding to a family of ligand-gated ion channels, stimulated
by acetylcholine (ACh) or nicotine Which causes the ion
channel to open and cations to ?ux With a resulting rapid

35

(millisecond) depolarization of the target cell.
Neuronal nicotinic receptors are composed of tWo types of
subunits, 0t and [3, and assemble as heteromeric receptors With
the general stoichiometry of 2a and 3[3 or as homomeric
receptors With 5a subunits. Nine subtypes of the ot subunit

40

(a2 to (x10) and three subtypes of the [3 unit ([32 to [34) are

Q and T are each independently attached to R1 and R2. Q
and T are each independently selected from alkyl, substituted

alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi
tuted arylalkynyl, heterocyclic, substituted heterocyclic;
SOYl, SOZYI, SOZOYl or SO2NHY1, where Y1 is selected

found in the central nervous system. The mo st common nico

from hydrogen, loWer alkyl, alkenyl, alkynyl or aryl, and

tinic receptor subtype in the brain is composed of tWo (X4 and

where Y1 is not hydrogen in SOYl and if Y1 is alkenyl or
alkynyl, the site of unsaturation is not conjugated With a

three [32 subunits, i.e., (X462. These subunits display different,
but overlapping, patterns of expression in the brain. Examples
of heteromeric receptor subtypes include (X462, (X362, (X3 [34,

45

heteroatom; COY2, Where Y2 is selected from hydrogen,

50

alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted
alkynyl, aryl, substituted aryl, aryloxy, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het

(X662, (x6[32[33, (x40t5[32, (x60t5[32, (x60t4[32, (x60t4[32[33,
(x4[32[34, (X3 [32[34, and others. The predominant homomeric
subtype includes (x7, but other combinations have also been

proposed.
For the most part, the actual subunit compositions and
stoichiometries of nicotinic receptors in the brain remain to

erocyclic, or substituted heterocyclic, and Where if Y2 com
prises alkenyl or alkynyl, the site of unsaturation is not

be elucidated. Thus, neuronal nicotinic receptor subtype
diversity originates from differences in the amino acid

conjugated With the carbonyl group; 0Y3, Where Y3 is
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,

sequence at the subunit level and from the multiple combina
tions of assemblies of subunits into functional receptor pro
teins, Which affords a Wide diversity of pharmacological

55

substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted

60

heterocyclic, Where if Y3 comprises alkenyl or alkynyl, the

speci?city.
In spite of the extensive diversity in neuronal nicotinic
receptor messenger RNA expression, only a limited number
of tools are available to study the pharmacology of native
receptors. Radioligands are used in many studies. [3H]NIC

site of unsaturation is not conjugated With the oxygen;

NY4Y5, Where Y4 and Y5 are each independently selected

appears to label the same sites in the brain as [3H]ACh. It has

been estimated that over 90% of [3H]NIC binding in the brain
is due to association With the heteromeric receptor that is
composed of (X4 and [32 subunits. Also abundant in the central
nervous system are the homomeric receptors labeled by [3 H]

65

from hydrogen, alkyl, substituted alkyl, cycloalkyl, substi
tuted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substi
tuted alkynyl, aryl, substituted aryl, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl,

US 8,653,275 B2
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3
alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted het
erocyclic, Where ifY4 orY5 comprises alkenyl or alkynyl, the
site of unsaturation is not conjugated With the nitrogen; SY6,
Where Y6 is selected from hydrogen, alkyl, substituted alkyl,

A9 is carbon or nitrogen, provided that WhenA9 joins a ring
atom With an unsaturated bond or is a nitrogen, R19 is absent,
and When A9 joins a ring atom With an unsaturated bond and
is a nitrogen, both R19 and R20 are absent.

cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk

A10 is carbon or nitrogen, provided that When A10 joins a

enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alky
laryl, substituted alkylaryl, arylalkyl, substituted arylalkyl,
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted

ring atom With an unsaturated bond or is a nitrogen, R21 is
absent, and When A10 joins a ring atom With an unsaturated
bond and is a nitrogen, both R21 and R22 are absent.

arylalkynyl, heterocyclic, or substituted heterocyclic, and
Where if Y6 comprises alkenyl or alkynyl, the site of unsat
uration is not conjugated With the sulfur.

ring atom With an unsaturated bond or is a nitrogen, R23 is

All is carbon or nitrogen, provided that When All joins a
absent, and When All joins a ring atom With an unsaturated
bond and is a nitrogen, both R23 and R24 are absent.

R1 and R2 are each independently ?ve or six membered

R3’ R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ R13 and R14’ or
R15’ R16’ R17’ R18’ R19’ R20’ R21’ R22’ R23 and R24’ When

rings as shoWn in formulas (HA) and (HE), Wherein each ring
of R1 and R2 has one, tWo or three nitrogen atoms, each ring
of R1 and R2 has one quaterniZed nitrogen, and tWo of R3
through R24 of each R1 and tWo of R3 through R24 of each R2

present, are each independently selected from hydrogen,

are replaced by one attachment to Q and one attachment to T.

(IIA)

20

alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryla
lkyl, substituted arylalkyl, arylalkenyl, substituted arylalk
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, sub
stituted heterocyclic, halo, cyano, nitro; or tWo adjacent

groups R3 through R14, or groups R15 through R24, together
With the atoms to Which they are attached on the ring of (HA)
or (IIB) independently form a three to eight member cyclol
25

kane, substituted cycloalkane, cycloalkene, substituted
cycloalkene, aryl, substituted aryl, heterocycle With one to
three hetero atoms of nitrogen, oxygen or sulfur in the ring, or
substituted heterocycle With one to three hetero atoms of
nitrogen, oxygen or sulfur in the ring; and When all of the

(HE)
30

bonds to the ring ammonium nitrogen are saturated, then any

OfR3’ R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ R13’ R14’ R15’ R16,
R17, R18, R19, R20, R21, R22, R23 or R24 Which is attached to
the ammonium nitrogen is a straight or branched alkyl group
of four carbons or feWer.
35

A1 is carbon or nitrogen, provided that WhenAl joins a ring
atom With an unsaturated bond or is a nitrogen, R3 is absent,
and When A1 joins a ring atom With an unsaturated bond and
is a nitrogen, both R3 and R4 are absent.

A2 is carbon or nitrogen, provided that When A2 joins a ring

40

atom With an unsaturated bond or is a nitrogen, R5 is absent,
and When A2 joins a ring atom With an unsaturated bond and
is a nitrogen, both R5 and R6 are absent.

tively modulating the function of a nicotinic acetylcholine
receptor comprising administering a therapeutically effective
amount of a compound as described above to a mammalian

subject in need thereof.

A3 is carbon or nitrogen, provided that When A3 joins a ring
atom With an unsaturated bond or is a nitrogen, R7 is absent,
and When A3 joins a ring atom With an unsaturated bond and
is a nitrogen, both R7 and R8 are absent.

In another embodiment, a composition is provided com
prising a pharmaceutically acceptable carrier and a com
pound as described above.
In another embodiment, a method is provided for selec

45

In another embodiment, a method is provided for facilitat
ing transport of a compound of the invention into the central
nervous system by interaction of the compound With the
blood brain barrier choline transporter.
In another embodiment, a method is provided for prevent

A4 is carbon or nitrogen, provided that When A4 j oins a ring

ing and/ or treating a central nervous system associated disor

atom With an unsaturated bond or is a nitrogen, R9 is absent,
and When A4 joins a ring atom With an unsaturated bond and
is a nitrogen, both R9 and R10 are absent.

der, for example, schizophrenia, Tourettes’, Huntington’s
50

Chorea, Parkinson’s disease, AlZheimer’s disease, and
related conditions, comprising administering a therapeuti

A5 is carbon or nitrogen, provided that When A5 joins a ring

cally effective amount of a compound as described above to a

atom With an unsaturated bond or is a nitrogen, R1 l is absent,

mammalian subject in need thereof.
In another embodiment, a method is provided for prevent
ing and/or treating substance use and/or abuse comprising

and When A5 joins a ring atom With an unsaturated bond and
is a nitrogen, both R11 and R12 are absent.

55

A6 is carbon or nitrogen, provided that When A6 joins a ring

administering a therapeutically effective amount of a com

pound as described above to a mammalian subject in need
thereof.

atom With an unsaturated bond or is a nitrogen, R13 is absent,
and When A6 joins a ring atom With an unsaturated bond and
is a nitrogen, both R13 and R14 are absent.

A7 is carbon or nitrogen, provided that When A7 joins a ring

In another embodiment, a method is provided for prevent
60

atom With an unsaturated bond or is a nitrogen, R15 is absent,
and When A7 joins a ring atom With an unsaturated bond and
is a nitrogen, both R15 and R16 are absent.

administering a therapeutically effective amount of a com

pound as described above to a mammalian subject in need
thereof.

A8 is carbon or nitrogen, provided that When A8 joins a ring
atom With an unsaturated bond or is a nitrogen, R17 is absent,
and When A8 joins a ring atom With an unsaturated bond and
is a nitrogen, both R17 and R18 are absent.

ing and/ or treating gastrointestinal tract disorders comprising

Other methods, features and advantages of the present
65

invention Will be or become apparent to one With skill in the

art upon examination of the folloWing detailed descriptions. It
is intended that all such additional methods, features and

US 8,653,275 B2
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advantages be included Within this description, be Within the
scope of the present invention, and be protected by the accom

cyclic, halogen, tri?uoromethyl, cyano, nitro, amino, car
boxyl, carbamate, sulfonyl, and sulfonamide.

panying claims.

The term “cycloalkyl” refers to cyclic ring-containing moi
eties containing 3 to 8 carbon atoms, and “substituted
cycloalkyl” refers to cycloalkyl moieties further bearing one

DETAILED DESCRIPTION OF THE INVENTION

or more substituents as set forth above.

Before the present compositions and methods are
described, it is to be understood that the invention is not

The term “alkenyl” refers to straight or branched chain
hydrocarbyl groups having at least one carbon-carbon double
bond and having 2 to 19 carbon atoms, and “substituted
alkenyl” refers to alkenyl groups further bearing one or more

limited to the particular methodologies, protocols, assays,
and reagents described, as these may vary. It is also to be
understood that the terminology used herein is intended to

substituents as set forth above.

describe particular embodiments of the present invention, and

The term “alkynyl” refers to straight or branched chain

is in no Way intended to limit the scope of the present inven
tion as set forth in the appended claims.
It must be noted that as used herein and in the appended

hydrocarbyl moieties having at least one carbon-carbon triple
bond and having 2 to 19 carbon atoms, and “substituted
alkynyl” refers to alkynyl moieties further bearing one or

claims, the singular forms “a,” “an,” and “the” include plural

more substituents as set forth above.

references unless the context clearly dictates otherWise.
Unless de?ned otherWise, all technical and scienti?c terms
used herein have the same meanings as commonly under
stood by one of ordinary skill in the art to Which this invention
belongs. All publications cited herein are incorporated herein

The term “aryl” refers to aromatic groups having 6 to 24
carbon atoms, and “substituted aryl” refers to aryl groups
20

The term “alkylaryl” refers to alkyl-substituted aryl
groups, and “substituted alkylaryl” refers to alkylaryl groups

by reference in their entirety for the purpose of describing and

further bearing one or more substituents as set forth above.

disclosing the methodologies, reagents, and tools reported in
the publications that might be used in connection With the

further bearing one or more substituents as set forth above.

25

The term “arylalkyl” refers to aryl-substituted alkyl
groups, and “substituted arylalkyl” refers to arylalkyl groups

invention. Nothing herein is to be construed as an admission

further bearing one or more substituents as set forth above.

that the invention is not entitled to antedate such disclosure by

The term “arylalkenyl” refers to aryl-substituted alkenyl
groups, and “substituted arylalkenyl” refers to arylalkenyl

virtue of prior invention.
The term “nicotinic acetylcholine receptor” refers to the

endogenous acetylcholine receptor having binding sites for

groups further bearing one or more substituents as set forth
30

acetylcholine Which also bind to nicotine. The term “nicotinic

The term “arylalkynyl” refers to aryl-substituted alkynyl
groups, and “substituted arylalkynyl” refers to arylalkynyl

acetylcholine receptor” includes the term “neuronal nicotinic

acetylcholine receptor.”
The terms “subtype of nicotinic acetylcholine receptor,”
and “nicotinic acetylcholine receptor subtype” refer to vari

groups further bearing one or more substituents as set forth
35

ous subunit combinations of the nicotinic acetylcholine
receptor, and may refer to a particular homomeric or hetero
meric complex, or multiple homomeric or heteromeric com

above.
The term “heterocyclic” refers to cyclic moieties contain
ing one or more heteroatoms as part of the ring structure and

having 3 to 24 carbon atoms, and “substituted heterocyclic”

plexes.
The term “choline transporter” refers to the endogenous

above.

40

refers to heterocyclic moieties further bearing one or more
substituents as set forth above.

choline transporter having binding sites for choline Which
also bind to positively charged quaternary ammonium

The term “acyl” refers to alkyl-carbonyl groups, and “sub
stituted acyl” refers to acyl groups further bearing one or

groups. The term “choline transporter” includes the term

more substituents as set forth above.

“blood brain barrier choline transporter.”
The term “agonist” refers to a substance Which interacts
With a receptor and increases or prolongs a physiological

45

polymers arrived at by de?ning sub stituents With further sub
stituents to themselves (e. g. substituted aryl having a substi

response (i.e. activates the receptor).
The term “partial agonist” refers to a substance Which
interacts With and activates a receptor to a lesser degree than
an agonist.
The term “antagonist” refers to a substance Which interacts
With and decreases the extent or duration of a physiological
response of that receptor.
The terms “disorder,” “disease,” and “condition” are used
inclusively and refer to any status deviating from normal.
The term “central nervous system associated disorders”

50

refers to alkyl radicals further bearing one or more substitu

ents including, but not limited to, hydroxy, alkoxy (of a loWer

alkyl group), mercapto (of a loWer alkyl group), aryl, hetero

tuted aryl group as a substituent Which is itself substituted
With a substituted aryl group, etc.) are not intended for inclu
sion herein. In such cases, the maximum number of such
substituents is three. That is to say that each of the above

de?nitions is constrained by a limitation that, for example,
substituted aryl groups are limited to -substituted aryl-(sub
55

stituted aryl)-sub stituted aryl.
Compounds of the present invention are bis-quaternary

ammonium cyclophane compounds corresponding to For
mula (I):

includes any cognitive, neurological, and mental disorders
causing aberrant or pathological neural signal transmission,
such as disorders associated With the alteration of normal
neurotransmitter release in the brain.
The term “loWer alkyl” refers to straight or branched chain
alkyl radicals having in the range of l to 4 carbon atoms.
The term “alkyl” refers to straight or branched chain alkyl
radicals having 1 to 19 carbon atoms, and “substituted alkyl”

The term “halogen” refers to ?uoride, chloride, bromide or
iodide groups.
It is understood that in all substituted groups de?ned above,

60

65

X16 and X26 are each independently an organic or inor

ganic anion.

US 8,653,275 B2
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Q and T are each independently attached to R1 and R2. Q
and T are each independently selected from alkyl, substituted

-continued
R24

alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi
tuted arylalkynyl, heterocyclic, substituted heterocyclic;
SOYl, SO2Y1, SO2OYl or SO2NHYl, where Y1 is selected

(HB)

from hydrogen, lower alkyl, alkenyl, alkynyl or aryl, and
where Y1 is not hydrogen in SOYl and if Y1 is alkenyl or
alkynyl, the site of unsaturation is not conjugated With a

Al is carbon or nitrogen, provided that WhenAl joins a ring
atom With an unsaturated bond or is a nitrogen, R3 is absent,
and When A1 joins a ring atom With an unsaturated bond and
is a nitrogen, both R3 and R4 are absent.

heteroatom; COY2, Where Y2 is selected from hydrogen,

alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted
alkynyl, aryl, substituted aryl, aryloxy, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het
erocyclic, or substituted heterocyclic, and Where if Y2 com
prises alkenyl or alkynyl, the site of unsaturation is not

A2 is carbon or nitrogen, provided that When A2 joins a ring
atom With an unsaturated bond or is a nitrogen, R5 is absent,
and When A2 joins a ring atom With an unsaturated bond and
is a nitrogen, both R5 and R6 are absent.

A3 is carbon or nitrogen, provided that When A3 joins a ring
20

conjugated With the carbonyl group; 0Y3, Where Y3 is
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,

substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted

A4 is carbon or nitrogen, provided that When A4 joins a ring
25

A5 is carbon or nitrogen, provided that When A5 joins a ring

site of unsaturation is not conjugated With the oxygen;

from hydrogen, alkyl, substituted alkyl, cycloalkyl, substi
tuted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substi
tuted alkynyl, aryl, substituted aryl, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl,
alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted het
erocyclic, Where ifY4 orY5 comprises alkenyl or alkynyl, the
site of unsaturation is not conjugated With the nitrogen; SY6,
Where Y6 is selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk

30

A6 is carbon or nitrogen, provided that When A6 joins a ring

35

are replaced by one attachment to Q and one attachment to T.

A7 is carbon or nitrogen, provided that When A7 joins a ring
atom With an unsaturated bond or is a nitrogen, R15 is absent,
and When A7 joins a ring atom With an unsaturated bond and
is a nitrogen, both R15 and R16 are absent.

A8 is carbon or nitrogen, provided that When A8 joins a ring
40

atom With an unsaturated bond or is a nitrogen, R17 is absent,
and When A8 joins a ring atom With an unsaturated bond and
is a nitrogen, both R17 and R18 are absent.

A9 is carbon or nitrogen, provided that When A9 joins a ring
45

atom With an unsaturated bond or is a nitrogen, R19 is absent,
and When A9 joins a ring atom With an unsaturated bond and
is a nitrogen, both R19 and R20 are absent.

A10 is carbon or nitrogen, provided that When A10 joins a

R1 and R2 are each independently ?ve or six membered

rings as shoWn in formulas (HA) and (HB), Wherein each ring
of R1 and R2 has one, tWo or three nitrogen atoms, each ring
of R1 and R2 has one quaterniZed nitrogen, and tWo of R3
through R24 of each R1 and tWo of R3 through R24 of each R2

and When A5 joins a ring atom With an unsaturated bond and
is a nitrogen, both R11 and R12 are absent.

atom With an unsaturated bond or is a nitrogen, R13 is absent,
and When A6 joins a ring atom With an unsaturated bond and
is a nitrogen, both R13 and R14 are absent.

enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alky
laryl, substituted alkylaryl, arylalkyl, substituted arylalkyl,
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted
arylalkynyl, heterocyclic, or substituted heterocyclic, and
Where if Y6 comprises alkenyl or alkynyl, the site of unsat
uration is not conjugated With the sulfur.

atom With an unsaturated bond or is a nitrogen, R9 is absent,
and When A4 joins a ring atom With an unsaturated bond and
is a nitrogen, both R9 and R10 are absent.
atom With an unsaturated bond or is a nitrogen, R1 1 is absent,

heterocyclic, Where if Y3 comprises alkenyl or alkynyl, the
NY4Y5, Where Y4 and Y5 are each independently selected

atom With an unsaturated bond or is a nitrogen, R7 is absent,
and When A3 joins a ring atom With an unsaturated bond and
is a nitrogen, both R7 and R8 are absent.

50

ring atom With an unsaturated bond or is a nitrogen, R21 is
absent, and When A10 joins a ring atom With an unsaturated
bond and is a nitrogen, both R21 and R22 are absent.

All is carbon or nitrogen, provided that When All joins a
ring atom With an unsaturated bond or is a nitrogen, R23 is

absent, and When All joins a ring atom With an unsaturated
bond and is a nitrogen, both R23 and R24 are absent.
55

R3’ R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ R13 and R14’ or
R15’ R16’ R17’ R18’ R19’ R20’ R21’ R22’ R23 and R24’ When
present, are each independently selected from hydrogen,

60

alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryla
lkyl, substituted arylalkyl, arylalkenyl, substituted arylalk
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, sub
stituted heterocyclic, halo, cyano, nitro; or tWo adjacent

groups R3 through R14, or groups R15 through R24, together
65

With the atoms to Which they are attached on the ring of (HA)
or (HB) independently form a three to eight member cyclol

kane, substituted cycloalkane, cycloalkene, substituted

US 8,653,275 B2
9

10
tahydro-indole, octahydro-cyclopenta[b]pyrrole, l-methy

cycloalkene, aryl, substituted aryl, heterocycle With one to
three hetero atoms of nitrogen, oxygen or sulfur in the ring, or
substituted heterocycle With one to three hetero atoms of
nitrogen, oxygen or sulfur in the ring; and When all of the

loctahydro-cyclopenta[b]pyrrole, decahydroquinoline, and

bonds to the ring ammonium nitrogen are saturated, then any

OfR3’ R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ R13’ R14’ R15’ R16,

HSO4_, S04‘, HPO4_, PO42‘, methanesulfonate, tri?uo
romethane sulfate, p-toluenesulfonate, benZenesulfonate,

R17, R18, R19, R20, R21, R22, R23 or R24 Which is attached to
the ammonium nitrogen is a straight or branched alkyl group

salicylate, proprionate, ascorbate, aspar‘tate, fumarate, galac
tarate, maleate, citrate, glutamate, glycolate, lactate, malate,

of four carbons or feWer.

maleate, tartrate, oxalate, succinate, or similar pharmaceuti

l -methyldecahydroquinoline.
X16 and X26, for example, include F', Cl“, Br“, I“, N02“,

cally acceptable organic acid addition salts, including the

For example, R1 and R2 include pyrrole, pyrrolidine, pyra

Zole, imidaZole, 1,2,3-triazole, l,2,4-triaZole, pyridine, pyri
midine, piperidine, quinoline, tetrahydroquinoline, isoquino
line, tetrahydroisoquinoline, pyraZine, piperaZine, pyridaZine

pharmaceutically acceptable salts listed in the Journal of

and triaZine.

be in some cases hydrates or solvates With alcohols and other

As another example, R3, R4, R5, R6, R7, R8, R9, R10, R11,
R12’ R13’ R14’ R15’ R16’ R17’ R18’ R19’ R20’ R21’ R22’ R23 and
R24, include hydrogen, methyl, ethyl, propyl, butyl,

solvents.
In a compound of Formula (I), preferably R1 and R2 are

hydroxymethyl, hydroxyethyl, hydroxypropyl, tri?uorom
ethyl, chloro, bromo, phenyl, pyrrolidine, N-alkyl pyrrolidine

are pyridinium rings, such as 1,3-substituted pyridinium

(for example Where the alkyl chain is methyl, ethyl or propyl),

Pharmaceutical Sciences volume 66, page 2, 1977, Which are

hereby incorporated by reference. The above salt forms may

six-membered, aromatic rings. More preferably, R1 and R2

rings.
20

In a compound of Formula (I), preferably R3, R4, R5, R6,

unsaturated pyrrolidine, unsaturated N-alkyl pyrrolidine (for

R7’ R8’ R9’ R10’ R11’ R12’ R13’ R14’ R15’ R16’ R17’ R18’ R19’

example Where the alkyl chain is methyl, ethyl or propyl),

R20, R21, R22, R23 or R24 is absent or is hydrogen.

aZiridine, N-methyl aZiridine, aZetidine, N-methyl aZetidine,

In a compound of Formula (I), preferably Q is attached to
the nitrogen of a pyridinium ring of R1 and R2. In other
preferred embodiments, Q is attached to the nitrogen of a

unsaturated aZetidine, unsaturated N-methyl aZetidine, pip
eridine, N-methyl piperidine, unsaturated piperidine, unsat
urated N-methyl piperidine, aZepane, N-methyl aZepane,

25

pyridinium ring of R1 and a carbon at the 3-position of a

pyridinium ring of R2. Preferably, Q is an alkyl group; more

unsaturated aZepane, unsaturated N-methyl aZepane, aZo
cane, N-methyl aZocane, unsaturated aZocane, unsaturated

N-methyl aZocane, l-aZa-bicyclo[3.2.l]octane, l-aZa-bicy

clo[2.2.l]heptane,
8-methyl-8-aZa-bicyclo[3.2.l]octane,
l-aZa-tricyclo[3.3.l.l3’7]decane, methyl cycloalkyl, methyl
substituted cycloalkyl, methylpyrrolidine, methyl N-alkyl
pyrrolidine (for example Where the alkyl chain is methyl,
ethyl or propyl), methyl unsaturated pyrrolidine, methyl
unsaturated N-alkyl pyrrolidine (for example Where the alkyl
chain is methyl, ethyl or propyl), methyl aZiridine, methyl
N-methyl aZiridine, methyl aZetidine, methyl N-methyl aZe
tidine, methyl unsaturated aZetidine, methyl unsaturated

30

In a compound of Formula (I), preferably T is attached to

the carbon at the 3-position of a pyridinium ring of R1 and R2.
In other preferred embodiments, T is attached to the nitrogen
35

N-methyl aZetidine, methyl piperidine, methyl N-methyl pip
eridine, methyl unsaturated piperidine, methyl unsaturated
N-methyl piperidine, methyl aZepane, methyl N-methyl

40

In another embodiment, the compound of Formula (I) is
de?ned wherein R1 and R2 are 1,3-substituted pyridinium

aZepane, methyl unsaturated aZepane, methyl unsaturated
N-methyl aZepane, methyl aZocane, methyl N-methyl aZo
cane, methyl unsaturated aZocane, methyl unsaturated N-me

thyl aZocane, methyl-l-aZa-bicyclo[3.2.l]octane, methyl-l

aZa-bicyclo[2.2.l]heptane,

rings: Q is *(CH2)4*> i(CH2)6i$ i(CH2)8is
*(CH2)9*> *(CH2)10*: *(CH2)11* or *(CH2)12*: T
45

8-methyl-8-aZa-bicyclo[3.2.l]

Exemplary compounds of the present invention include:
N,N'-(l ,6-hexanediyl)-3,3'-(l ,9-decanediyn-l , l 0-diyl)-bis

As a further example, When tWo adjacent groups R3

pyridinium diiodide;

through R14, or groups R15 through R24, together With the
50

stituted cycloalkane, cycloalkene, substituted cycloalkene,

N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn- l , l 0-diyl)-bis

pyridinium dibromide;

aryl, substituted aryl, heterocycle With one to three hetero

N,N'-(l , l 0-decanediyl)-3,3'-(l ,9-decanediyn-l , l0-diyl)-bis
55

gen or sulfur in the ring. For example, possible rings include

benZo[b]thiophene,

bis-pyridinium dibromide;

benZo[c]thiophene,

indole, indolenine, isoindole, cyclopental[b]pyridine, pyrano
[3,4-b]pynrole, indaZole, indoxaZine, benZoxaZole, anthranil,
naphthalene, tetralin, decalin, chromene, coumarin, chro
man-4-one, isocoumarin, isochromen-3-one, quinoline, iso

quinoline, cinnoline, quinaZoline, naphthyrdine, pyrido[3,4
b]-pyridine, pyridol[3,2-b]pyridine, pyrido[4,3,-b]-pyridine,
benZoxaZine, anthracene, phenanthrene, phenalene, ?uorene,

pyridinium diiodide;
N,N'-(l ,l l-undecanediyl) -3 ,3'-( l , 9-decanediyn- l , l 0-diyl)

benZene, pyridine, pyran, indene, isoindene, benZofuran,

isobenZofuran,

N,N'-(l ,8-octananediyl) -3 ,3'-( l , 9-decanediyn- l , l 0-diyl)

bis-pyridinium diiodide;

independently form a three to eight member cyclolkane, sub
atoms of nitrogen, oxygen or sulfur in the ring, or substituted
heterocycle With one to three hetero atoms of nitrogen, oxy

is i(CH2) 12* or 4CECi(CH2)6iCECi, and X1 and
X2 are bromide or iodide.

octane, and methyl-l -aZa-tricyclo[3.3 .l .l3’7]decane.
atoms to Which they are attached on the ring of (IIA) or (IIB)

of a pyridinium ring of R2 and a carbon at the 3-position of a
pyridinium ring of R1. Preferably, T is an alkyl group or a
4CEC-alkyl-CEC-group; more preferably, T is selected
from i(CH2) 12* or iCECi(CH2)6iCECi.
In a compound of Formula (I), preferably X16 and X26 are
halogens. More preferably, X16 and X26 are bromide or
iodide.

N,N'-(l ,4-butanediyl) -3 ,3'-(l , l 2-dodecanediyl) -bis-pyri
dinium diiodide;
60

N,3'-(l,l2-dodecanediyl)-3,N'-(l,l2-dodecanediyl)-bis-py
ridinium dibromide.
The compounds of the present invention may contain one
or more stereocenters. The invention includes all possible
diastereomers and all enantiomeric forms as Well as all com

caraZole, xanthene, acnidine, octahydro-[l]pyridine, l-me

binations of diasteriomers and enantiomers, including race
mic mixtures. The compounds can be separated into substan

thyloctahydro-[l]pyridine, octahydroindole, l-methyloc

tially optically pure compounds.
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Compounds of the present invention can be prepared, for
example, from corresponding bases by reaction With an

In another embodiment, the present invention is directed to
a method for preventing and/or treating a central nervous

line receptor agents. Thus, they may augment or inhibit [3 H]

system associated disorder comprising administering to a
mammalian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the

nicotine binding, [3H]MLA binding, evoke or inhibit neu

compound of Formula (I) may selectively bind to one or more

appropriate alkyl bromide.
The compounds of the invention are nicotinic acetylcho

rotransmitter release, and/or evoke or inhibit the ?ux of ions

subtypes of nicotinic acetylcholine receptor. The compound

through the nicotinic receptor. Moreover, the compounds of

of Formula (I) may act as an agoinst or partial agonist of
nicotinic acetylcholine receptor function. Hence the com
pound of Formula (I) may increase or prolong the release of a

the invention may act either at presynaptic sites or postsyn

aptic sites, for example, at a postsynaptic acetylcholine recep

neurotransmitter from a central nervous system tissue. The

tor containing an (X7 subunit. When acting at a postsynaptic
site, neurotransmitter release per se is not altered. Rather, the

neurotransmitter affected may include dopamine, norepi

nephrine, serotonin, gamma-aminobutryic acid, or glutamate.

compounds of the invention may act by interacting With a

Alternatively, the compound of Formula (I) may act as an

postsynaptic acetylcholine receptor to change the membrane
potential of the cell, thereby increasing or decreasing the

antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent

likelihood of ?ring an action potential. Alternatively, interac

or duration of the release of a neurotransmitter from a central

tion of a compound of the invention With a postsynaptic
acetylcholine receptor may result in the alteration of one or

nervous system tissue. In this regard, the compound of For
mula (I) may act by decreasing stimulant-evoked neurotrans
mitter release. The neurotransmitter affected may include

more second messenger systems Within the cell so as to 20

decrease or increase the nicotinic cholinergic response.
In one embodiment, the present invention relates to a
method for selectively modulating the function of a nicotinic
acetylcholine receptor comprising administering to a mam
malian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the
compound of Formula (I) may selectively bind to one or more

dopamine, norepinephrine, serotonin, gamma-aminobutryic
acid, or glutamate. Alternatively, the compound of Formula
(I) may act by interacting With a postsynaptic acetylcholine
receptor to change the membrane potential of the cell thereby
25

subtypes of nicotinic acetylcholine receptor. The compound
of Formula (I) may act as an agoinst or partial agonist of
nicotinic acetylcholine receptor function. Hence the com
pound of Formula (I) may increase or prolong the release of a
neurotransmitter from a central nervous system tissue. The

cholinergic response.
Central nervous system disorders Which may be treated
30

cluding disorders of attention, focus and concentration),
attention de?cit disorders, affective disorders, extrapyrami

nephrine, serotonin, gamma-aminobutryic acid, or glutamate.

dal motor function disorders, Parkinson’s disease, progres
35

antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central

nervous system tissue. In this regard, the compound of For
mula (I) may act by decreasing stimulant-evoked neurotrans

40

mitter release. The neurotransmitter affected may include

sive supramolecular palsy, Huntington’s disease, Gilles de la
Tourette syndrome, tardive dyskinesia, neuroendocrine dis
orders, dysregulation of food intake, disorders of nociception,
pain, mood and emotional disorders, depression, panic anxi
ety, psychosis, schizophrenia, or epilepsy.
In yet another embodiment, the present invention is
directed to a method for preventing and/ or treating sub stance
use and/or abuse comprising administering to a mammalian
subject in need thereof a therapeutically effective amount of a

dopamine, norepinephrine, serotonin, gamma-aminobutryic
acid, or glutamate. Alternatively, the compound of Formula
(I) may act by interacting With a postsynaptic acetylcholine
receptor to change the membrane potential of the cell thereby

according to the method of the present invention include

AlZheimer’s disease, dementia, cognitive dysfunctions (in

neurotransmitter affected may include dopamine, norepi
Alternatively, the compound of Formula (I) may act as an

increasing or decreasing the likelihood of ?ring an action
potential, or to alter one or more second messenger systems
Within the cell so as to decrease or increase the nicotinic

compound of Formula (I). In such a method, the compound of
45

Formula (I) may selectively bind to one or more subtypes of

increasing or decreasing the likelihood of ?ring an action

nicotinic acetylcholine receptor. The compound of Formula

potential, or to alter one or more second messenger systems
Within the cell so as to decrease or increase the nicotinic

tylcholine receptor function. Hence the compound of For

(I) may act as an agonist or partial agonist of nicotinic ace

cholinergic response.
In another embodiment, the present invention is directed to
a method of facilitating transport of a compound of Formula
(I) into the central nervous system by interaction of the com
pound With the blood brain barrier choline transporter. Com

50

neurotransmitter affected may include dopamine, norepi

nephrine, serotonin, gamma-aminobutryic acid, or glutamate.
Alternatively, the compound of Formula (I) may act as an

antagonist of nicotinic acetylcholine receptor function.

pounds of Formula (I) have high af?nity for blood brain
barrier choline transporters and have the potential to be

mula (I) may increase or prolong the release of a neurotrans
mitter from a central nervous system tissue. The

55

Hence the compound of Formula (I) may decrease the extent

actively transported into the CNS by this transporter. Choline

or duration of the release of a neurotransmitter from a central

transport at the blood brain barrier is a sodium-independent,
carrier-mediated, and saturable process. The choline trans
porter binding site contains an anionic binding area that binds

nervous system tissue. In this regard, the compound of For
mula (I) may act by decreasing stimulant-evoked neurotrans
mitter release. The neurotransmitter affected may include

positively charged quaternary ammonium groups. Recent

60

Formula (I) provides a unique synergistic combination of
nicotinic receptor interaction and af?nity for the blood brain
barrier choline transporter to maximiZe transport into the
central nervous system.

dopamine, norepinephrine, serotonin, gamma-aminobutryic
acid, or glutamate. Alternatively, the compound of Formula
(I) may act by interacting With a postsynaptic acetylcholine
receptor to change the membrane potential of the cell thereby

reports have shoWn that this transporter is ef?cacious in deliv
ering quaternary ammonium analogs to the CNS. The quater
nary ammonium structural characteristic of the compounds of

increasing or decreasing the likelihood of ?ring an action
65

potential, or to alter one or more second messenger systems
Within the cell so as to decrease or increase the nicotinic

cholinergic response.
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compound of Formula (I) may act by decreasing stimulant

The conditions of substance use and/or abuse treated

according to the method of the present invention include
nicotine abuse (including use in smoking cessation therapy),

evoked neurotransmitter release. The neurotransmitter

affected may include dopamine, norepinephrine, serotonin,
gamma-aminobutryic acid, or glutamate. Alternatively, the

nicotine intoxication, amphetamine abuse, methamphet
amine abuse, MDMA (methylenedioxymethamphetamine)
abuse, methylphenidate abuse, cocaine abuse, or alcohol

compound of Formula (I) may act by interacting With a

postsynaptic acetylcholine receptor to change the membrane
potential of the cell thereby increasing or decreasing the

abuse.
In another embodiment, the present invention is directed to

likelihood of ?ring an action potential, or to alter one or more
second messenger systems Within the cell so as to decrease or

a method for preventing and/or treating gastrointestinal tract
disorders comprising administering to a mammalian subject

increase the nicotinic cholinergic response.
In?ammatory disorders Which may be treated according to
the method of the present invention include adult respiratory

in need thereof a therapeutically effective amount of a com

pound of Formula (I). In such a method, the compound of

distress syndrome, allergy, anemia, ankylosing spondylitis,
asthma, atherosclerosis, bacterial infections, benign prostatic

Formula (I) may selectively bind to one or more subtypes of

nicotinic acetylcholine receptor. The compound of Formula

hyperplasia, cholecystitis, ulcerative colitis, Crohn’s disease,
diabetes mellitus, emphysema, gastritis, glomerulonephritis,
hypereosinophilia, irritable boWel syndrome, multiple scle
rosis, osteoarthritis, pancreatitis, polymyositis, psoriasis and

(I) may act as an agonist or partial agonist of nicotinic ace

tylcholine receptor function. Hence the compound of For
mula (I) may increase or prolong the release of a neurotrans
mitter from a central nervous system tissue, or may increase
or prolong the release of a neurotransmitter from a peripheral
nervous system tissue, or may act directly on a gastrointesti
nal tract tissue. The neurotransmitter affected may include

20

rheumatoid arthritis.
The compounds of the present invention can be delivered

directly or in pharmaceutical compositions along With suit

dopamine, norepinephrine, serotonin, gamma-aminobutryic

able carriers or excipients, as is Well knoWn in the art. For

acid, or glutamate. Alternatively, the compound of Formula

example, a pharmaceutical composition of the invention may

(I) may act as an antagonist of nicotinic acetylcholine recep
tor function. Hence the compound of Formula (I) may

include a conventional additive, such as a stabiliZer, buffer,
25

decrease the extent or duration of the release of a neurotrans
mitter from a central nervous system tissue, or may decrease
the extent or duration of the release of a neurotransmitter from
a peripheral nervous system tissue, or may act directly on a

gastrointestinal tract tissue. In this regard, the compound of
Formula (I) may act by decreasing stimulant-evoked neu
rotransmitter release. The neurotransmitter affected may

salt, preservative, ?ller, ?avor enancer and the like, as knoWn
to those skilled in the art. Exemplary buffers include phos

phates, carbonates, citrates and the like. Exemplary preserva
tives include EDTA, EGTA, BHA, BHT and the like.
30

An effective amount of such agents can readily be deter
mined by routine experimentation, as can the most effective
and convenient route of administration and the most appro

priate formulation. Various formulations and drug delivery

include dopamine, norepinephrine, serotonin, gamma-ami

systems are available in the art. See, e.g., Gennaro, A. R., ed.

nobutryic acid, or glutamate. Alternatively, the compound of

(1995) Remington’s Pharmaceutical Sciences.

Formula (I) may act by interacting With a postsynaptic ace

35

tylcholine receptor to change the membrane potential of the
cell thereby increasing or decreasing the likelihood of ?ring

Suitable routes of administration may, for example,

include oral, rectal, transmucosal, transdermal, topical, nasal,
or intestinal administration and parenteral delivery, including

an action potential, or to alter one or more second messenger

intramuscular, subcutaneous, intramedullary injections, as

systems Within the cell so as to decrease or increase the

Well as intrathecal, direct intraventricular, intravenous, intra
peritoneal, intranasal, or intraocular injections. In addition,
the agent or composition thereof may be administered sub

nicotinic cholinergic response.
Gastrointestinal disorders Which may be treated according

40

to the method of the present invention include irritable boWel

lingually or via a spray, including a sublingual tablet or a

syndrome, colitis, diarrhea, constipation, gastric acid secre

sublingual spray. The agent or composition thereof may be

tion or ulcers.

administered in a local rather than a systemic manner. For

In yet another embodiment, the present invention is
directed to a method for preventing and/ or treating in?am
matory tract disorders comprising administering to a mam

example, a suitable agent can be delivered via injection or in
a targeted drug delivery system, such as a depot or sustained
release formulation.

malian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the

may be manufactured by any of the methods Well-knoWn in

compound of Formula (I) may selectively bind to one or more

45

The pharmaceutical compositions of the present invention
50

the art, such as by conventional mixing, dissolving, granulat

subtypes of nicotinic acetylcholine receptor. The compound

ing, dragee-making, levigating, emulsifying, encapsulating,

of Formula (I) may act as an agonist or partial agonist of
nicotinic acetylcholine receptor function. Hence the com
pound of Formula (I) may increase or prolong the release of a

entrapping, or lyophiliZing processes. As noted above, the

neurotransmitter from a central nervous system tissue, or may
increase or prolong the release of a neurotransmitter from a
peripheral nervous system tissue, or may act directly on a
non-nervous system tissue. The neurotransmitter affected

may include dopamine, norepinephrine, serotonin, gamma
aminobutryic acid, or glutamate. Alternatively, the compound

compositions of the present invention can include one or
55
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of Formula (I) may act as an antagonist of nicotinic acetyl
choline receptor function. Hence the compound of Formula
(I) may decrease the extent or duration of the release of a
neurotransmitter from a central nervous system tissue, or may
decrease the extent or duration of the release of a neurotrans
mitter from a peripheral nervous system tissue, or may act

directly on a non-nervous system tissue. In this regard, the

more physiologically acceptable carriers such as excipients
and auxiliaries that facilitate processing of active molecules
into preparations for pharmaceutical use.
Proper formulation is dependent upon the route of admin

istration chosen. For injection, for example, the composition
may be formulated in aqueous solutions, preferably in physi
ologically compatible buffers such as Hanks’ solution, Ring
er’ s solution, or physiological saline buffer. For transmucosal
or nasal administration, penetrants appropriate to the barrier
to be permeated are used in the formulation. Such penetrants
are generally knoWn in the art. In a preferred embodiment of

65

the present invention, the present compounds are prepared in
a formulation intended for oral administration. For oral

administration, the compounds can be formulated readily by
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combining the active compounds With pharmaceutically

multi-dose containers, With an added preservative. The com
positions may take such forms as suspensions, solutions, or
emulsions in oily or aqueous vehicles, and may contain for

acceptable carriers Well known in the art. Such carriers enable
the compounds of the invention to be formulated as tablets,

pills, dragees, capsules, liquids, gels, syrups, slurries, suspen

mulatory agents such as suspending, stabilizing and/or dis
persing agents. Formulations for parenteral administration

sions and the like, for oral ingestion by a subject. The com
pounds may also be formulated in rectal compositions such as

include aqueous solutions or other compositions in Water
soluble form.

suppositories or retention enemas, e.g., containing conven
tional suppository bases such as cocoa butter or other glyc
erides.
Pharmaceutical preparations for oral use canbe obtained as

Suspensions of the active compounds may also be prepared

as appropriate oily injection suspensions. Suitable lipophilic
solvents or vehicles include fatty oils such as sesame oil and

solid excipients, optionally grinding a resulting mixture, and

synthetic fatty acid esters, such as ethyl oleate or triglycer
ides, or liposomes. Aqueous injection suspensions may con
tain substances that increase the viscosity of the suspension,
such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension may also contain suitable stabiliz

processing the mixture of granules, after adding suitable aux
iliaries, if desired, to obtain tablets or dragee cores. Suitable

excipients are, in particular, ?llers such as sugars, including
lactose, sucrose, mannitol, or sorbitol; cellulose preparations
such as, for example, maize starch, Wheat starch, rice starch,

ers or agents that increase the solubility of the compounds to

potato starch, gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcel
lulose, and/or polyvinylpyrrolidone (PVP). If desired, disin
tegrating agents may be added, such as the cross-linked poly

alloW for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in poWder form for
constitution With a suitable vehicle, e.g., sterile pyrogen-free
20

Water, before use.

vinyl pyrrolidone, agar, or alginic acid or a salt thereof such as

As mentioned above, the compositions of the present

sodium alginate. Also, Wetting agents such as sodium dodecyl

invention may also be formulated as a depot preparation.

sulfate may be included.
Dragee cores are provided With suitable coatings. For this
purpose, concentrated sugar solutions may be used, Which

Such long acting formulations may be administered by
implantation (for example, subcutaneously or intramuscu
larly) or by intramuscular injection. Thus, for example, the
present compounds may be formulated With suitable poly

25

may optionally contain gum arabic, talc, polyvinyl pyrroli
done, carbopol gel, polyethylene glycol, and/or titanium
dioxide, lacquer solutions, and suitable organic solvents or
solvent mixtures. Dyestuffs or pigments may be added to the
tablets or dragee coatings for identi?cation or to characterize
different combinations of active compound doses.

30

Suitable carriers for the hydrophobic molecules of the

Pharmaceutical preparations for oral administration
include push-?t capsules made of gelatin, as Well as soft,
sealed capsules made of gelatin and a plasticizer, such as
glycerol or sorbitol. The push-?t capsules can contain the
active ingredients in admixture With ?ller such as lactose,

invention are Well knoWn in the art and include co-solvent

systems comprising, for example, benzyl alcohol, a nonpolar
35

binders such as starches, and/or lubricants such as talc or

magnesium stearate and, optionally, stabilizers. In soft cap
sules, the active compounds may be dissolved or suspended in
suitable liquids, such as fatty oils, liquid paraf?n, or liquid
polyethylene glycols. In addition, stabilizers may be added.
All formulations for oral administration should be in dosages
suitable for such administration.
In one embodiment, the compounds of the present inven
tion can be administered transderrnally, such as through a skin
patch, or topically. In one aspect, the transderrnal or topical
formulations of the present invention can additionally com
prise one or multiple penetration enhancers or other effectors,
including agents that enhance migration of the delivered com
pound. Transderrnal or topical administration could be pre

40

surfactant, a Water-miscible organic polymer, and an aqueous
phase. The co-solvent system may be the VPD co-solvent
system. VPD is a solution of 3% W/v benzyl alcohol, 8% W/v

of the nonpolar surfactant polysorbate 80, and 65% W/v poly
ethylene glycol 300, made up to volume in absolute ethanol.
The VPD co-solvent system (VPD15W) consists of VPD
diluted 1:1 With a 5% dextrose in Water solution. This co

solvent system is effective in dissolving hydrophobic com

pounds and produces loW toxicity upon systemic administra
tion. Naturally, the proportions of a co-solvent system may be
45

varied considerably Without destroying its solubility and tox
icity characteristics. Furthermore, the identity of the co-sol
vent components may be varied. For example, other loW
toxicity nonpolar surfactants may be used instead of

50

ferred, for example, in situations in Which location speci?c
delivery is desired.
For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered
in the form of an aerosol spray presentation from pressurized

meric or hydrophobic materials (for example as an emulsion
in an acceptable oil) or ion exchange resins, or as sparingly
soluble derivatives, for example, as a sparingly soluble salt.

polysorbate 80, the fraction size of polyethylene glycol may
be varied, other biocompatible polymers may replace poly
ethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars
or polysaccharides may substitute for dextrose.

Alternatively, other delivery systems for hydrophobic mol

packs or a nebulizer, With the use of a suitable propellant, e.g.,

ecules may be employed. Liposomes and emulsions are Well
knoWn examples of delivery vehicles or carriers for hydro

dichlorodi?uoromethane, trichloro?uoromethane, dichlo

phobic drugs. Liposomal delivery systems are discussed

rotetra?uoroethane, carbon dioxide, or any other suitable gas.
In the case of a pressurized aerosol, the appropriate dosage
unit may be determined by providing a valve to deliver a

above in the context of gene-delivery systems. Certain
organic solvents such as dimethylsulfoxide also may be

55

60

employed, although usually at the cost of greater toxicity.
Additionally, the compounds may be delivered using sus
tained-release systems, such as semi-permeable matrices of
solid hydrophobic polymers containing the effective amount
of the composition to be administered. Various sustained

65

release materials are established and available to those of skill

metered amount. Capsules and cartridges of, for example,
gelatin, for use in an inhaler or insuf?ator may be formulated.

These typically contain a poWder mix of the compound and a
suitable poWder base such as lactose or starch.

Compositions formulated for parenteral administration by
injection, e. g., by bolus injection or continuous infusion can

be presented in unit dosage form, e.g., in ampoules or in

in the art. Sustained-release capsules may, depending on their
chemical nature, release the compounds for a feW Weeks up to

US 8,653,275 B2
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over 100 days. Depending on the chemical nature and the

Example 1

biological stability of the therapeutic reagent, additional
strategies for stabilization may be employed.

Preparation of

Compoundl,10-bis-[(pyridin-3-yl)]-1,9-decadiyne

For any composition used in the present methods of treat
ment, a therapeutically effective dose can be estimated ini

tially using a variety of techniques Well knoWn in the art. For
example, in a cell culture assay, a dose can be formulated in
animal models to achieve a circulating concentration range

I

that includes the lC5O as determined in cell culture. Dosage
ranges appropriate for human subjects can be determined, for
example, using data obtained from cell culture assays and
other animal studies.

+

N

Pd(PPh3)2Cl2/CuI
—

(CH2)6

—

pyrrolidine

(CH2)s

%
| \

% | \

/

/

N

N

1,9-Decanediyne (2.8 g, 20.9 mmol) and 3-bromopyridine
(50 mmol) Were mixed in pyrrolidine folloWed by the addi
tion of Pd(PPh3)2Cl2 (50 mg) and Cul (50 mg). The mixture
25

Was heated to 60-700 C. for 2 h. The solvent Was removed in

vacuum and the residue Was subjected chromatography. Hex
ane and ethyl acetate 10:1 elute out 3-bromopyridine and 2:1

centrations that includes the ED5O With little or no toxicity.

Dosages may vary Within this range depending upon the
dosage form employed and the route of administration uti
liZed. The exact formulation, route of administration, and
dosage should be chosen, according to methods knoWn in the
art, in vieW of the speci?cs of a subject’s condition.
The amount of agent or composition administered Will, of
course, be dependent on a variety of factors, including the sex,

Br

/

A therapeutically effective dose of an agent refers to that
amount of the agent that results in amelioration of symptoms
or a prolongation of survival in a subject. Toxicity and thera

peutic ef?cacy of such molecules can be determined by stan
dard pharmaceutical procedures in cell cultures or experi
mental animals, e. g., by determining the LD5O (the dose lethal
to 50% of the population) and the ED5O (the dose therapeuti
cally effective in 50% of the population). The dose ratio of
toxic to therapeutic effects is the therapeutic index, Which can
be expressed as the ratio LDSO/EDSO. Agents that exhibit high
therapeutic indices are preferred.
Dosages preferably fall Within a range of circulating con

\

hexane and ethyl acetate elute out the product (5.1 g, 85%
30

yield) as oil. HNMR (300 MHZ, D20) 8.59 (d, 1:15 HZ, 2H),
8.43 (dd, J:1.8 HZ, 1:51 HZ, 2H), 7.62 (dt, J:1.8 HZ, J:7.8
HZ, 2H), 7.15 (ddd, 1:09 HZ, 1:48 HZ, J:7.8 HZ, 2H), 2.40

(t, 1:69 HZ, 4H), 1.59-1.63 (m, 4H), 1.46-1.49 (m, 4H).
Example 2
35

age, and Weight of the subject being treated, the severity of the

Preparation of Compound N,N'-(1,6-hexanediyl)-3,

affliction, the manner of administration, and the judgment of

3'-(1,9-decanediyn-1,10-diyl)-bis-pyridinium diio

the prescribing physician.

dide

The present compositions may, if desired, be presented in a
pack or dispenser device containing one or more unit dosage
forms containing the active ingredient. Such a pack or device
may, for example, comprise metal or plastic foil, such as a

blister pack. The pack or dispenser device may be accompa
nied by instructions for administration. Compositions com
prising a compound of the invention formulated in a compat
ible pharmaceutical carrier may also be prepared, placed in an
appropriate container, and labeled for treatment of an indi
cated condition.
These and other embodiments of the present invention Will

40

(CHM;

45

50

readily occur to those of ordinary skill in the art in vieW of the

disclosure herein, and are speci?cally contemplated.
EXAMPLES

The invention is further understood by reference to the
folloWing examples, Which are intended to be purely exem
plary of the invention. The present invention is not limited in
scope by the exempli?ed embodiments, Which are intended as

55

3,3'-(1,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol)
and an equivalent of 1,6-diiodohexane Were mixed in aceto
60

ods that are functionally equivalent are Within the scope of the
invention. Various modi?cations of the invention in addition
to those described herein Will become apparent to those
skilled in the art from the foregoing description. Such modi
?cations fall Within the scope of the appended claims.

nitrile (1000 mL). The mixture Was re?uxed for 7 days. The
solvent Was removed in vacuum after cooling and the result
ing residue Was taken up in Water and partitioned betWeen
ethyl ether and Water. The aqueous layer Was extracted exten
sively With ethyl ether remove the starting materials. Most of

illustrations of single aspects of the invention only. Any meth

65

the Water Was removed and the residue Was transferred into
methanol. Methanol Was removed and the product Was dried

under vacuum to afford the bis-pyridinium cyclophane (30%

US 8,653,275 B2
19

20

yield). HNMR (300 MHZ, D20) 8.76 (s, 2H), 8.56 (d, 1:60
HZ, 2H), 8.29 (d, 1:84 HZ, 2H), 7.81 (dd, 1:63 HZ, 8.1 HZ,
2H), 4.40 (1, 1:75 HZ, 4H), 2.39 (1, 1:63 HZ, 4H), 1.85-1.84
(m, 4H), 1.49-1.52 (m, 4H), 1.38-1.42 (m, 4H), 1.18-1.22 (m,
4H). CNMR, 146.97, 146.26, 142.61, 128.00, 125.71,
101.43, 73.93, 61.99, 29.94, 27.84, 27.49, 24.43, 18.90.

-continued

Example 3

Preparation of Compound N,N'-(1,8-octanediyl)-3,

3,3'-(1,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol)

3'-(1,9-decanediyn-1,10-diyl)-bis-pyridinium diio

and an equivalent of 1,9-dibromononane Were mixed in

acetonitrile (1000 mL). The mixture Was re?uxed for 7 days.
The solvent Was removed in vacuo after cooling and the
resulting residue Was taken up in Water and partitioned
betWeen diethyl ether and Water. The aqueous layer Was

extracted extensively With diethyl ether remove the starting
materials. Mo st of the Water Was removed and the residue Was
transferred into methanol. Methanol Was removed and the

product Was dried under vacuum to afford the bis-pyridinium

25

cyclophane (38% yield) HNMR (300 MHZ, D20) 10.39 (s,
2H), 9.52 (d, 1:57, 2H), 8.18 (d, 1:75, 8.00 (m, 2H), 5.06 (t,
J:7.2, 4H), 2.49 (t, 1:63, 4H), 2.08-2.18 (br, 4H), 1.60-1.80
(br, 12H), 1.42-1.56 (br, 8H), 1.37-1.40 (br, 2H).
Example 5

Preparation of Compound N,N'-(1,10-decanediyl)-3,
3'-(1,9-decanediyn-1,10-diyl)-bis-pyridinium diio
dide
35

3,3'-(1,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol)

(CH2)6

and an equivalent of 1,8-diiodooctane Were mixed in aceto

nitrile (1000 mL). The mixture Was re?uxed for 7 days. The
solvent Was removed in vacuo after cooling and the resulting
residue Was taken up in Water and partitioned betWeen diethyl
ether and Water. The aqueous layer Was extracted extensively
With diethyl ether to remove the starting materials. Most of
the Water Was removed and the residue Was transferred into
methanol. Methanol Was removed and dried under vacuum to

afford the bis-pyridinium cyclophane (35% yield). HNMR
(300 MHZ, D20) 10.30 (s, 2H), 9.37 (d, 1:57, 2H), 8.19 (d,
1:81, 2H), 7.94 (dd, 1:81, 1:60, 2H), 4.95 (t, 1:84, 4H),
2.49 (t, 1:66, 4H), 2.14-2.22 (m, 4H), 1.75-1.85 (m, 4H),
1.61-1.68 (m, 8H), 1.54-1.58 (br, 8H), 1.49-4.58 (br, 4H).

I \

/
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\
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I \
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3,3'-(1,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol)

Example 4

and an equivalent of 1,10-diiododecane Were mixed in aceto

nitrile (1000 mL). The mixture Was re?uxed for 7 days. The

Preparation of Compound N,N'-(1,9-nonanediyl)-3,

55

3'-(1,9-decanediyn-1,10-diyl)-bis-pyridinium dibro
mide

solvent Was removed in vacuo after cooling and the resulting
residue Was taken up in Water and partitioned betWeen diethyl
ether and Water. The aqueous layer Was extracted extensively
With diethyl ether remove the starting materials. Most of the
Water Was removed and the residue Was transferred into

60

(CH2)6

/

\

0% \@ T
I N/

methanol. Methanol Was removed and the product Was dried

under vacuum to afford the bis-pyridinium cyclophane (40%

I

/

N

yield). HNMR (300 MHZ, D20), 10.11 (s, 2H), 9.37 (d, 1:63,
2H), 8.22 (dt, 1:78, 1:12, 2H), 8.03 (dd, 1:63, 1:78, 2H),
4.99 (t, 1:81, 4H), 2.49 (t, 1:66, 4H), 2.15-2.17 (m, 4H),
1.38-1.75 (m, 24H). CNMR, 147.73, 145.88, 142.71, 128.04,
126.46, 102.54, 74.29, 61.82, 32.44, 28.71, 27.90, 27.83,
27.40, 25.81, 20.21.
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Example 6

mL) at —780 C. The mixture Was stirred for 30 min and then

Preparation of Compound N,N'-(1,11-undecanediyl)

Was added drop-Wise. The resulting mixture Was Warmed to

3,3'-(1,9-decanediyn-1,10-diyl)-bis-pyridinium

room temperature and stirred for 4 hrs. Fifty percent saturated
NH4Cl Was added to the reaction mixture. The aqueous phase
Was extracted With ethylacetate (2><40 mL), and the combined
organic liquors Were Washed With 50% saturated brine (3x40

1,10-dibromodecane (6.43 g, 16.32 mmol) in THF (10 mL)
dibromide

mL) and saturated brine (40 mL), dried over anhydrous
Na2SO4, and concentrated under reduced pres sure. The crude

product Was puri?ed by column chromatography (hexanes:
ethylacetate 2:1 to 1 :1) to afford 3 .98 g of the title compound.

Yield: 75%. 1H NMR (300 MHZ, CDCl3) 6 1.17-1.40 (m,
16H), 1.53-1.68 (m, 4H), 2.60 (t, 1:75 HZ, 4H), 7.20 (dd,
J:7.8, 1.8 HZ, 2H), 7.48 (dt, J:7.8, 1.8 HZ, 2H), 8.43 (d, 1:51
HZ, 2H), 8.44 (s, 2H) ppm; 13C NMR (75 MHZ, CDCl3) 6

29.4, 29.7, 29.8, 29.9, 31.4, 33.3, 123.3, 135.8, 138.4, 147.2,
150.0 ppm.

Example 8

Preparation of Compound N,N'-(1,4-butanediyl)-3,
3'-(1,12-dodecanediyl)-bis-pyridinium diiodide

3,3'-(1,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol)
and an equivalent of 1,11-dibromoundecane Were mixed in

acetonitrile (1000 mL). The mixture Was re?uxed for 7 days.
The solvent Was removed in vacuo after cooling and the
resulting residue Was taken up in Water and partitioned
betWeen diethyl ether and Water. The aqueous layer Was

30

extracted extensively With diethyl ether remove the starting
materials. Mo st of the Water Was removed and the residue Was
transferred into methanol. Methanol Was removed and the 35

product Was dried under vacuum to afford the bis-pyridinium

cyclophane (42% yield). HNMR (300 MHZ, D20), 9.92 (s,
2H), 9.48 (d, 1:78, 2H), 8.22 (d, J:8.1, 2H), 8.05 (m, 2H),
5.08 (br, 4H), 2.49 (t, 1:63, 4H), 2.05-2.15 (br, 4H), 1.70
1.82 (br, 12H), 1.55-1.65 (br, 4H), 1.45-1.55 (br, 4H), 1.30

40

1.45 (8H).
Example 7

Preparation of Compound

1,12-bis-(pyridin-3 -yl)-dodecane

45

50

3,3'-(Dodecan-1,12-diyl)-bis-pyridine (1 mmol) and an
equivalent of 1,4-diiodobutane Were mixed in 4-methyl-2
pentanol (265 mL). The mixture Was re?uxed for 28 days. The
solvent Was removed in vacuo after cooling and the resulting
residue Was taken up in methylene chloride and Water (50 mL,

1:1). The methylene chloride layer containing the mono
55

quatemary ammonium product Was removed and the remain

ing aqueous layer further extracted With methylene chloride

(3x25 mL). The Water layer containing the bis-pyridinium
product Was evaporated under reduced pressure to loW vol
60

ume (0.5 mL) and transferred into methanol (5 mL). The
methanol Was removed and the product Was dried under

vacuum to afford the bis-pyridinium cyclophane (3 5% yield).
/
N
65

LDA (2M) (20.40 mL, 40.80 mmol) Was added drop-Wise
to a solution of 3-picoline (3.80 g, 40.80 mmol) in THF (60

1H NMR (300 MHZ, CD3OD) 6 1.21-1.46 (m, 16H), 1.72 (m,
4H), 2.18 (m, 4H), 2.56 (s, 6H), 2.81 (t, 1:75 HZ, 4H), 4.68
(m, 4H), 8.28 (s, 2H), 8.79 (s, 2H), 8.83 (s, 2H) ppm; 13C
NMR (75 MHZ, CD3OD) 6 18.8, 28.8, 28.9, 29.4, 29.6, 30.8,
33.5, 61.7, 140.9, 142.3, 143.3, 144.9, 147.6 ppm.
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Example 9

13c NMR (75 MHZ, @3013) 6 25.5, 28.5, 28.8, 28.9, 29.0,
29.9, 30.7, 31.7, 60.5, 127.4, 142.1, 142.8, 143.8, 144.9 ppm.

Preparation of Compound
Example 11

12-(pyridin-3-yl)-1-bromododecane

Inhibition of [3H]nicotine and

[3H]Methyllycaconitine Binding Assays
Whole brain, excluding cortex and cerebellum, Was

homogenized in 20 vol of ice-cold buffer, containing (in
mM): 2 HEPES, 11.8 NaCl, 0.48 KCl, 0.25 CaCl2 and 0.12
MgSO4, pH 7.5. Homogenate Was centrifuged (25,000 g, 15
min, 40 C.). Pellets Were resuspended in 20 vol buffer and
incubated at 37° C., for 10 min, cooled to 40 C. and centri

fuged (25,000 g, 15 min, 4° C.). Pellets Were resuspended and
centrifuged using the same conditions. Final pellets Were

LDA (2 M) (10.5 mL, 21.22 mmol) Was added drop-Wise to
a solution of3-picoline (2.17 g, 23.34 mmol) in THF (60 mL)

20

at —78° C. The mixture Was stirred for 30 min and then

1,1 1-dibromoundecane (10 g, 31.83 mmol) Was added in one
portion. The resulting mixture Was Warmed to 0° C. and
stirred for 4 hrs. Fifty percent saturated NH4Cl Was added to
the reaction mixture. The aqueous phase Was extracted With

(MLA), and bis-quatemary ammonium cyclophane analog
(100 nM) in assay buffer containing 50 mM Tris. Control Was
25

puri?ed by column chromatography (hexanes:ethylacetate

respectively. Incubations proceeded for 60 min at room tem
30

4:1) to afford 4.47 g 12-(pyridin-3-yl)-1-bromododecane.
Yield: 59%.

Example 10

in the absence of analog. In [3H]nicotine and [3H]methylly
caconitine binding assays, nonspeci?c binding Was deter
mined in the presence of 10 pM cytisine and 10 pM nicotine,

ethylacetate (2><40 mL), and the combined organic liquors
Were Washed With 50% saturated brine (3x40 mL) and satu
rated brine (40 mL), dried over anhydrous Na2SO4, and con
centrated under reduced pressure. The crude product Was

stored in assay buffer, containing (in mM): 20 HEPES, 118
NaCl, 4.8 KCl, 2.5 CaCl2, and 1.2 MgSO4, pH 7.5 at —70° C.
Upon use, ?nal pellets Were resuspended in ~20 vol assay
buffer. Samples (250 pl) contained 100-140 pg of membrane
protein, 3 nM [3H]nicotine or 3 nM [3H]methyllycaconitine

35

Preparation of Compound N,3'-(1,12-dodecanediyl)
3,N'-(1, 12-dodecanediyl)-bis-pyridinium dibromide

perature using 96-Well plates and Were terminated by harvest
ing on Uni?lter-96 GF/ B ?lterplates presoaked in 0.5% poly
ethylenimine, using a Packard FilterMate harvester. After
Washing 5 times With 350 pl ice-cold assay buffer, ?lter plates
Were dried (60 min, 4° C.), bottom-sealed, and ?lled With
Packard’s MicroScint 20 cocktail (40 pl/Well). After 60 min,
?lter plates Were top-sealed, and radioactivity determined
using a Packard TopCount. Protein concentrations Were

determined using the Bradford dye-binding procedure bovine
serum albumin as the standard. The results are summarized in
40

\

I

Example 12

Br

/
N

I \

2/

45

ZBre

Table 1.

Rat striatal slices (500 pm thickness, 6-8 mg Wet Weight)

/g I
\

Were incubated for 30 minutes in Krebs buffer (118 mM
50

The solvent Was removed in vacuo after cooling and the

55

to a glass superfusion chamber. Slices Were superfused (1.0
mL/min) for 60 minutes With Krebs buffer containing

rial Was removed and the remaining aqueous layer further
extracted With diethyl ether (3x25 mL). The Water layer con
60

reduced pressure to loW volume (0.5 mL) and transferred into
methanol (5 mL). The methanol Was removed and the product

nomifensine (10 pM) and pargyline (10 pM) and maintained
at 34° C., pH 7.4, With continual aeration (95% O2/5% CO2).
TWo ?ve minute samples (5 mL each) Were collected to deter
mine basal out?oW of [3H]DA. The bis-quatemary ammo
nium cyclophane analogs Were added to the superfusion
buffer after the collection of the second sample and remained

Was dried under vacuum to afford the bis-pyridinium cyclo

phane (25% yield). 1H NMR (300 MHZ, DMSO-d6) 6 1.15
1.39 (m, 32H), 1.63 (m, 4H), 1.90 (m, 4H), 2.78 (t, J:7.8 HZ,
4H), 4.57 (t, J:7.2 HZ, 4H), 8.08 (dd, 1:81, 6.0 HZ, 2H), 8.48
(d, J:8.1 HZ, 2H), 8.98 (d, 1:60 HZ, 2H), 9.10 (s, 2H) ppm;

0.1 pM [3 H] dopamine (DA; 6 slices/3 mL). Subsequently,
slices Were rinsed With 15 mL of fresh buffer and transferred

mL, 1: 1). The diethyl ether layer containing the starting mate
taining the bis-pyridinium product Was evaporated under

NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 1.0 mM NaH2PO4, 1.3
mM CaCl2, 11.1 mM glucose, 25 mM NaHCO3, 0.11 mM
L-ascorbic acid, and 0.004 mM disodium EDTA; pH 7.4, and
saturated With 95% 02/ 5% CO2) in a metabolic shaker at 34°
C. Slices Were rinsed With 15 mL of fresh buffer and incu
bated for an additional 30 minutes in fresh buffer containing

12-(Pyridin-3-yl)-1-bromododecane Was dissolved in
acetonitrile (250 mL). The mixture Was re?uxed for 24 hours.

resulting residue Was taken up by Water and diethyl ether (50

Inhibition of Nicotine-evoked [3H]Neurotransmitter
Release Assay

65

in the buffer until 12 consecutive ?ve minute samples Were

collected. Subsequently, S-(—)-nicotine (10 pM) Was added to
the buffer and an additional 12 consecutive ?ve minute

US 8,653,275 B2
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samples Were collected. At the end of the experiment, each
slice Was solubiliZed and the [3 H] content of the tissue deter
mined.
Radioactivity in the superfusate and tissue samples Was

striatal slices. In addition, the classical competitive nicotinic

determined by liquid scintillation spectroscopy. Fractional
release for tritium collected in each sample Was divided by the
total tritium present in the tissue at the time of sample collec
tion and Was expressed as a percentage of total tritium. Basal

[3H]out?oW Was calculated from the average of the tritium
collected in the tWo ?ve minute samples just before addition
of the quaternary ammonium analog. The sum of the increase
in collected tritium resulting from either exposure to the test
compound or exposure to S-(—)-nicotine in the absence and

presence of the test compound equaled total [3H]over?oW.
[3 H] Over?ow Was calculated by subtracting the [3 H] out?oW
during an equivalent period of prestimulation from the values
in samples collected during and after drug exposure. Inas
much as the radiolabelled compounds Were not separated and
identi?ed, the tritium collected in superfusate is referred to as

antagonist DHBE Was also examined in this assay for com

parison. None of the compounds examined had any signi?
cant [3H]DA releasing properties in this assay in the concen
tration range tested.

The bis-quaternary ammonium cyclophane analogs Were
also evaluated for their ability to inhibit nicotine evoked [3 H]
DA release. In these experiments, the striatal slices Were
superfused for 60 minutes With 100 nM concentration of the

bis-quaternary ammonium cyclophane analogs prior to nico
tine (l0 uM) exposure. Antagonist activity Was evaluated by
comparing the nicotine evoked [3H]over?oW in the absence
and presence of the analogs. The relative order of potency of

the bis-quaternary ammonium cyclophane analogs for inhi
bition of nicotine-evoked [3H]DA release from rat striatal
slices is illustrated in Table 1.

Table l. Bis-Quaternary Ammonium Cyclophane Com
pounds: Af?nity for the BBB Choline Transporter, Inhibition
either [3H]out?oW or [3H]over?oW, rather than as [3H]DA.
[3 H] Over?ow primarily represents [3H]DA in the presence of 20 of [3H]Nicotine and [3H]Methyllycaconitine (MLA) Binding
to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine
nomifensine and pargyline in the superfusion buffer.
evoked [3H]Dopamine Release from Superfused Rat Striatal
The bis-quaternary ammonium cyclophane analogs Were
Slices
evaluated for their ability to evoke [3H]DA release from rat

Inhibition of

A?'lnity for the

COMPOUND

Nicotine

BBB choline

Inhibition of

Inhibition of

evoked

transporter Ki

[3H]Nicotine

[3H]MLA

[3H]DA

(pM)

binding“

Bindingl7

releaseC

33.6

7%

2%

ND

ND

9%

0%

ND

1.4

0%

3%

ND

Example 2

Example 4
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-continued
Inhibition of

Af?nity for the

Nicotine

BBB choline

Inhibition of

Inhibition of

evoked

LI‘aHSpOI‘tcl‘ Ki

[3H]Nicotine

[3H]MLA

[3H]DA

(pM)

binding“

Bindingl7

releaseC

0.8

0.55 (Ki, uM)

4.64 (Ki, uM)

19%

15 .2

11%

3%

ND

ND

14 r 2.6%

3.0 r 3.0%

23%

NDd

2%

0%

20%

COMPOUND
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N

9

/® I
\

N

/® I

\

/

\

Example 5

K—\
N

l

@\

/

N

21

e

l

@\

/

Example 8

\
@/

N

9

ZBI

N

\

Example 10
Tata are % inhibition at 100 nM concentration of the bis-quaternary ammonium cyclophane analogs for at least l-3 independent experiments; With the exception of When
a Ki value in M is provided, in Which case a full concentration effect Was evaluated. Speci?c binding in the [3H]nicotine binding assay is calculated as the difference

betWeen the total binding of3 nM [3H]nicotine and nonspeci?c binding in the presence of 10 M cold cytisine.
bSpeci?c binding for the [3H]MLA binding assay is calculated as the difference betWeen the total binding of2.5 nM [3H]MLA to the receptors alone and its nonspeci?c
binding in the presence ofl uM cold nicotine.
CAnalog-induced inhibition ofnicotine-evoked [3H]DA release is calculated as a percent ofthat in the absence ofbis-quaternary ammonium cyclophane analog.
dND indicates not determined.

It Will be appreciated that, although speci?c embodiments 60
of the invention have been described herein for purposes of
illustration, various modi?cations may be made Without

departing from the spirit and scope of the invention. All such
modi?cations and variations are intended to be included 65
herein Within the scope of this disclosure and the present

invention and protected by the following claims.

We claim:
1- A Compound of Formula (I)
(I)

/Q\
X199 Rl\ /R2@ 9X2
T

US 8,653,275 B2
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3. The compound of claim 2, Wherein

wherein
X16 and X26 are each independently an organic or inor

X16 and X26 are bromide or iodide.
4. The compound of claim 1 selected from the group con

ganic anion;
Q and T are each independently attached to R1 and R2;

sisting of:

Q is alkyl;

N,N'-(l ,6-hexanediyl)-3,3'-(l,9-decanediyn- l , l0-diyl)

T is alkynyl;

bis-pyridinium diiodide;

R1 and R2 are each six membered rings as shoWn in formula

(HA);

N,N'-(l ,8-octananediyl)-3,3'-(l ,9-decanediyn-l , l 0-diyl)

bis-pyridinium diiodide;
10

R14

(HA)

R12

N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn-l , l 0-diyl)

bis-pyridinium dibromide;
N,N'-(l , l O-decanediyl) -3 ,3'-( l , 9-decanediyn- l , l 0-diyl)

bis-pyridinium diiodide; and
R4

‘l?

—

\

R6

/

R

10

R6, R8, R10, R12, and R14, When present, are each indepen
dently selected from the group consisting of hydrogen,

loWer alkyl, halo, cyano, nitro, tri?uoromethyl,
hydroxymethyl, hydroxyethyl and hydroxypropyl.
2. The compound of claim 1, Wherein Q is i(CH2)4i,

*(CH2)6< *(CH2)8< *(CH2)9< *(CH2)1O*,
i(CH2)1 1* or i(CH2)1 2i; and T is 4CECi(CH2)6i

diyl)-bis-pyridinium dibromide.
5. A composition comprising a pharmaceutically accept

R8

R8 or R12 is replaced by one attachment to T in R1 and R2;
R4 is replaced by one attachment to Q in R1 and R2;

CECi.

15

N,N'-(l ,l l'-undecanediyl)-3,3'-(l ,9-decanediyn-l ,10
able carrier and a compound of claim 1.

6. A composition comprising a pharmaceutically accept
20

able carrier and a compound of claim 2.

7. A composition comprising a pharmaceutically accept
able carrier and a compound of claim 3.

8. A composition comprising a pharmaceutically accept
able carrier and a compound of claim 4.
9. N,N'-(l ,4-butanediyl)-3,3'-(l , l 2-dodecanediyl)-bis-py
ridinium diiodide.

